Zoetis Beheer

Beheer criteriumcontroles 3/4

De CEO Zoetis is Kristin Peck, benoemd in Jan2020, heeft een ambtstermijn van 4.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.24M, bestaande uit 7.9% salaris en 92.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.018% van de aandelen van het bedrijf, ter waarde $ 14.33M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 11 jaar.

Belangrijke informatie

Kristin Peck

Algemeen directeur

US$15.2m

Totale compensatie

Percentage CEO-salaris	7.9%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	11yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kristin Peck's beloning veranderd ten opzichte van Zoetis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$15m	US$1m	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	US$14m	US$1m	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$13m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$2b
Dec 31 2020	US$10m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$3m	US$690k	US$2b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$1b
Dec 31 2018	US$3m	US$675k	US$1b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$978m
Dec 31 2017	US$3m	US$655k	US$864m

Compensatie versus markt: De totale vergoeding ($USD 15.24M ) Kristin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 5.72M ).

Compensatie versus inkomsten: De vergoeding van Kristin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kristin Peck (53 yo)

4.8yrs

Tenure

US$15,237,853

Compensatie

Ms. Kristin C. Peck serves as an Independent Director at BlackRock, Inc. since joining on September 29, 2021. She has been the Chief Executive Officer of Zoetis Inc. since January 01, 2020 and its Director...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kristin Peck	CEO & Director	4.8yrs	US$15.24m	0.018% $ 14.3m
Wetteny Joseph	Executive VP & CFO	3.4yrs	US$4.25m	0.0034% $ 2.7m
Wafaa Mamilli	EVP & Group President for China	no data	US$2.69m	0.0015% $ 1.2m
Robert Polzer	Executive VP and President of Research & Development	9.8yrs	US$2.44m	0.00095% $ 766.0k
Keith Sarbaugh	Executive VP & Chief Digital and Technology Officer	no data	geen gegevens	0.00022% $ 177.4k
Steven Frank	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Roxanne Lagano	Executive VP	less than a year	geen gegevens	0.0035% $ 2.8m
William Price	VP & Chief Communications Officer	no data	geen gegevens	geen gegevens
Julie Fuller	Executive VP	less than a year	geen gegevens	0.000020% $ 16.1k
Jeannette Astorga	Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer	4.2yrs	geen gegevens	0.00015% $ 120.9k
Nick Ashton	Executive VP and President of Global Manufacturing & Supply	2.5yrs	geen gegevens	0.00014% $ 112.9k
Jamie Brannan	Chief Commercial Officer	no data	geen gegevens	0.00043% $ 346.7k

2.5yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0M3Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kristin Peck	CEO & Director	5.1yrs	US$15.24m	0.018% $ 14.3m
Louise Parent	Independent Director	11.3yrs	US$370.00k	0.0030% $ 2.5m
Michael McCallister	Independent Non-Executive Chairman	11.8yrs	US$490.00k	0.0057% $ 4.6m
Paul Bisaro	Independent Director	9.5yrs	US$340.00k	0.0048% $ 3.9m
Frank D'Amelio	Independent Director	12.3yrs	US$340.50k	0.0033% $ 2.6m
Sanjay Khosla	Independent Director	11.4yrs	US$340.00k	0.0022% $ 1.7m
Robert Scully	Independent Director	11.4yrs	US$365.00k	0.0044% $ 3.5m
Gavin D. Hattersley	Independent Director	less than a year	geen gegevens	0.00017% $ 137.1k
Gregory Norden	Independent Director	11.8yrs	US$365.00k	0.0034% $ 2.7m
Willie Reed	Independent Director	10.7yrs	US$370.00k	0.0022% $ 1.8m
Vanessa Broadhurst	Independent Director	2.3yrs	US$341.00k	0.00023% $ 185.4k
Antoinette Leatherberry	Independent Director	3.9yrs	US$340.00k	0.00049% $ 395.1k

11.0yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0M3Q zijn ervaren en ervaren (gemiddelde ambtstermijn van 11 jaar).

Zoetis Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Zoetis Inc. Announces Executive Changes

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Zoetis Inc. Announces Executive Changes

Zoetis Inc., Annual General Meeting, May 22, 2024

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Insufficient new directors

Recent updates

Zoetis Inc. Announces Executive Changes

Zoetis Inc. Raises Revenue Guidance for the Full Year 2024

Third quarter 2024 earnings released: EPS: US$1.51 (vs US$1.30 in 3Q 2023)

Second quarter dividend of US$0.43 announced

Zoetis Inc. Declares Fourth Quarter 2024 Dividend, Payable on December 3, 2024

Zoetis to Introduce First Cartridge-Based AI-Powered Hematology Analyzer

Second quarter 2024 earnings released: EPS: US$1.37 (vs US$1.45 in 2Q 2023)

Zoetis Inc. Raises Earnings Guidance for the Year 2024

Zoetis Inc. (NYSE:ZTS) announces an Equity Buyback for $6,000 million worth of its shares.

Upcoming dividend of US$0.43 per share

First quarter dividend of US$0.43 announced

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Zoetis Inc. Declares Dividend for the Third Quarter of 2024, Payable on September 4, 2024

Zoetis Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$1.31 (vs US$1.19 in 1Q 2023)

Phibro Animal Health Corporation (NasdaqGM:PAHC) entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. (NYSE:ZTS) for approximately $350 million.

Zoetis Inc. Announces Executive Changes

Now 24% undervalued after recent price drop

Zoetis Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.43 per share

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Now 20% undervalued after recent price drop

Full year 2023 earnings released: EPS: US$5.08 (vs US$4.51 in FY 2022)

Dividend of US$0.43 announced

Zoetis Inc. Declares Second Quarter 2024 Dividend, Payable on June 4, 2024

Upcoming dividend of US$0.43 per share at 0.9% yield

Insufficient new directors

Zoetis Inc. Declares Dividend for the First Quarter of 2024, Payable on March 1, 2024

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$1.30 (vs US$1.13 in 3Q 2022)

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 1, 2023

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH.

Second quarter 2023 earnings released: EPS: US$1.45 (vs US$1.13 in 2Q 2022)

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Announces Appointment of Ester Banque as Executive Vice President and President, U.S. Operations

JAB Holdings B.V. acquired an unknown majority interest in Pumpkin Insurance Services Inc. from Zoetis Inc. (NYSE:ZTS).

Zoetis Inc. Declares Dividend for Third Quarter of 2023, Payable on September 1, 2023

Zoetis Inc. Announces U.S. Food and Drug Administration Approves Librela™ (Bedinvetmab Injection) for Control of Pain Associated with Osteoarthritis in Dogs

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: EPS: US$1.19 (vs US$1.26 in 1Q 2022)

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Provides Earning Guidance for Full Year 2023

Full year 2022 earnings released: EPS: US$4.51 (vs US$4.29 in FY 2021)

Zoetis Inc. Declares Second Quarter 2023 Dividend, Payable on June 1, 2023

Zoetis Inc. Announces Termination of Glenn David as Executive Vice President and Group President, U.S. Operations

Upcoming dividend of US$0.38 per share

Now 21% undervalued after recent price drop

Zoetis Inc. Declares Dividend for the First Quarter of 2023 Dividend, Payable on March 1, 2023

Third quarter 2022 earnings released: EPS: US$1.13 (vs US$1.17 in 3Q 2021)

Zoetis Inc. Provides Earnings Guidance for the Full Year 2022

Zoetis Inc. Announces Management Changes, Effective November 1, 2022

Upcoming dividend of US$0.33 per share

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2022, Payable on December 1, 2022

Second quarter 2022 earnings released: EPS: US$1.13 (vs US$1.08 in 2Q 2021)

Zoetis Inc. Provides Earnings Guidance for the Full Year 2022

Zoetis Inc. Appoints Vanessa Broadhurst to Its Board of Directors

Now 21% undervalued

Upcoming dividend of US$0.33 per share

Now 21% undervalued after recent price drop

Zoetis Inc.(NYSE:ZTS) dropped from Russell 1000 Value-Defensive Index

Zoetis Inc. (NYSE:ZTS) acquired Basepaws

Independent Director recently sold US$301k worth of stock

Zoetis Inc. (NYSE:ZTS) entered into an agreement to acquire Basepaws.

Now 23% undervalued after recent price drop

Zoetis Inc. Declares Dividend for the Third Quarter of 2022, Payable on September 1, 2022

First quarter 2022 earnings released: EPS: US$1.26 (vs US$1.18 in 1Q 2021)

Zoetis Inc. Revises Earnings Guidance for the Year 2022